CN114651014A - 用于治疗癌症的il-15融合肽 - Google Patents

用于治疗癌症的il-15融合肽 Download PDF

Info

Publication number
CN114651014A
CN114651014A CN202080067412.0A CN202080067412A CN114651014A CN 114651014 A CN114651014 A CN 114651014A CN 202080067412 A CN202080067412 A CN 202080067412A CN 114651014 A CN114651014 A CN 114651014A
Authority
CN
China
Prior art keywords
fusion polypeptide
seq
sequence
polypeptide
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080067412.0A
Other languages
English (en)
Chinese (zh)
Inventor
C·加卢斯蒂安
R·史密斯
D·斯莫拉雷克
E·帕帕伊万格罗
P·达斯古普塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prostate Cancer Research Center
Kings College London
Original Assignee
Prostate Cancer Research Center
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prostate Cancer Research Center, Kings College London filed Critical Prostate Cancer Research Center
Publication of CN114651014A publication Critical patent/CN114651014A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080067412.0A 2019-09-25 2020-09-25 用于治疗癌症的il-15融合肽 Pending CN114651014A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1913804.9 2019-09-25
GB201913804A GB201913804D0 (en) 2019-09-25 2019-09-25 Fusion polypeptides
PCT/GB2020/052328 WO2021058973A1 (en) 2019-09-25 2020-09-25 Il-15 fusion peptides used to treat cancer

Publications (1)

Publication Number Publication Date
CN114651014A true CN114651014A (zh) 2022-06-21

Family

ID=68425465

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080067412.0A Pending CN114651014A (zh) 2019-09-25 2020-09-25 用于治疗癌症的il-15融合肽

Country Status (9)

Country Link
US (1) US20220372097A1 (enExample)
EP (1) EP4034552A1 (enExample)
JP (1) JP2023502843A (enExample)
CN (1) CN114651014A (enExample)
AU (1) AU2020351698A1 (enExample)
CA (1) CA3155100A1 (enExample)
GB (1) GB201913804D0 (enExample)
IL (1) IL291560A (enExample)
WO (1) WO2021058973A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US20070160578A1 (en) * 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
GB0915519D0 (en) 2009-09-04 2009-10-07 King S College London Ntithrombotic compounds
WO2012054509A2 (en) * 2010-10-22 2012-04-26 Dana-Farber Cancer Institute, Inc. Discovery of regulatory t cells programmed to suppress an immune response
WO2018161026A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy
WO2019006472A1 (en) * 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
CA3086040A1 (en) * 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
AU2019228381B2 (en) * 2018-02-28 2021-12-16 Pfizer Inc. IL-15 variants and uses thereof
CA3090407A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15

Also Published As

Publication number Publication date
AU2020351698A1 (en) 2022-03-31
US20220372097A1 (en) 2022-11-24
EP4034552A1 (en) 2022-08-03
IL291560A (en) 2022-05-01
CA3155100A1 (en) 2021-04-01
JP2023502843A (ja) 2023-01-26
WO2021058973A1 (en) 2021-04-01
GB201913804D0 (en) 2019-11-06

Similar Documents

Publication Publication Date Title
RU2593947C2 (ru) Антагонисты wnt и способы лечения и тестирования
US9539341B2 (en) Methods and compositions for targeting adipose cells in mammals
JP2020005655A (ja) インターロイキン−２融合タンパク質及びその使用
CN107427574B (zh) Cxcr4结合分子
KR20210087108A (ko) 전립선 특이 막 항원 결합 단백질
AU2012251919B2 (en) Compositions for regulating iron homeostasis and methods of using same
JP2018515085A (ja) 抗がん融合ポリペプチド
CN104136041A (zh) 靶向硫酸软骨素聚糖
CN114651014A (zh) 用于治疗癌症的il-15融合肽
KR101687060B1 (ko) 모에신 조절제 및 그의 용도
JP6218175B2 (ja) ヘルパーｔ細胞誘導性ポリペプチドの改変
KR20180030552A (ko) 개질된 자가-에피토프에 대한 항종양 면역 반응
JP2013534814A (ja) Ｒｈａｍｍ結合ペプチド
US8252545B2 (en) Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methods
US20240115717A1 (en) Chlorotoxin derivatives and use thereof
KR101196799B1 (ko) 스태빌린-2의 ｅｇｆ-유사 도메인의 반복부위 단편을포함하는 폴리펩티드, 이를 포함하는 포스파티딜세린검출용 조성물 및 이의 용도
WO2024201004A1 (en) Combinatorial il-15 therapy
US20250352614A1 (en) Peptide therapeutics for the treatment of cancer and uses thereof
JPWO2019102710A1 (ja) ヒト癌細胞転移阻害薬およびヒト癌細胞判定薬
US20250263461A1 (en) Recombinant t-cell receptors that bind the ny-eso-1 and/or lage-1a cancer antigens
WO2026022392A1 (en) Peptide and conjugates thereof
JP2025511684A (ja) 新規ペプチドベースの免疫抗癌剤
KR100968838B1 (ko) 스태빌린-2의 ｅｇｆ-유사 도메인의 반복부위 단편을유효성분으로 포함하는 약물 전달용 조성물 및 이의 용도
CN116964074A (zh) 调节vegf的肽

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: London

Applicant after: Prostate Cancer Research Laboratory

Applicant after: KING'S College LONDON

Address before: London

Applicant before: Prostate cancer research center

Applicant before: KING'S College LONDON

CB02 Change of applicant information